Aliceblue ANTInstall and trade smarter everywhere
Complete IPO details, including price band, financials, subscription status, and key insights.
Participate in the Symbiotec Pharmalab Ltd IPO with full transparency. Review issue details, company fundamentals, and financial performance, and apply securely through Alice Blue.
Key metrics and details at a glance.
Price Band
₹988
Per ShareLot Size
15 Shares
Minimum Investment
₹14,820
Issue Size
₹1,757 Cr
Face Value
₹2
Per ShareIPO Type
Book Building
Retail Quota
35%
QIB Quota
50%
NII Quota
15%
Important dates for your applying strategy.
Business model, operations, and market positioning.
Promoter Holding (Pre-Issue)
36.39%
Promoter Holding (Post-Issue)
33.27%
Issue Type
Book Building
ISIN
INE899I01028
We are a research and development-driven, science-based pharmaceutical and biotechnology company with capabilities across three platforms-organic chemistry, biotechnology and complex injectables. We have a global leadership position in corticosteroid and steroidal-hormone active pharmaceutical ingredients ("APIs") in volume terms in Fiscal 2025, with a global volume market share of 36.2% in corticosteroid and 44.2% in steroidalhormone APIs. We have leveraged our capabilities to operate as a contract development and manufacturing organisation ("CDMO") for specialty pharmaceutical and nutraceutical companies.
The global API market is expected to grow at a 7.0% CAGR from 2024, reaching US$ 399.9 billion by 2029. The classical fermentation API market was valued at US$ 464.7 million in 2024 and is expected to grow at a CAGR of 0.5% to 2.5% between 2024 and 2029. The corticosteroid API market was valued at US$ 414.5 million in 2024, and it is estimated to grow at a moderate CAGR of 1.5 to 3.2% between 2024 and 2029. Further, CDMOs play a vital role in the pharmaceutical and biotechnology industries. The CMDO market is projected to grow at an 8.1% CAGR from 2024 to 2029, reaching US$ 190.2 billion.
Revenue, profit after tax and total assets across the last 3 reported financial years.
Amount in ₹ crore
How the company plans to utilize IPO proceeds.
The funds raised through this IPO will be used for:
Initial public offering of 17,786,442 equity shares of face value of Rs. 2 each ("Equity Shares") of the company for cash at a price of Rs. 988.00 per equity share ( Including a Share Premium of Rs. 986.00 Per Equity Share) ("Offer Price") aggregating Rs. 1757.00 Crores ("Offer"). The offer comprised a fresh issue of 1,521,261 equity shares of face value of Rs. 2 each aggregating Rs. 150.00 Crores by the company ("Fresh Issue") and an offer for sale of 16,265,181 equity shares of face value of Rs. 2 each ("Offered Shares") aggregating Rs.1607.00 Crores, comprising of 1,457,489 equity shares of face value of Rs. 2 each aggregating Rs. 144.00 Crores by Satwani Holdings LLP (the "Promoter Selling Shareholder"), 10,000,000 equity shares of face value of Rs. 2 each aggregating Rs.988.00 Crores by Rosewood Investments and 4,807,692 equity shares of face value of Rs. 2 each aggregating Rs. 475.00 Crores by India Business Excellence fund - III (the "Investor Selling Shareholders", and together with the promoter selling shareholder, the "Selling Shareholders" and such offer for sale of equity shares by the selling shareholders, the "Offer For Sale"). The offer will constituted 27.68% of the post-offer paid up equity share capital of the company. The offer includes a reservation of 33,407 equity shares of face value of Rs. 2 each aggregating Rs. 3.00 Crores ( Constituting 5% of the post offer paid-up equity share capital of the company), for subscription by eligible employees (the "Employee Reservation Portion"). The offer less the employee reservation portion is hereinafter referred to as the "Net Offer". The offer and the net offer shall constitute 27.68% and 27.63%, respectively, of the post-offer paid-up equity share capital of the company. The company, in consultation with the book running lead managers, may offer a discount of 9.11% (equivalent to Rs.90.00 per equity share) to the offer price to eligible employees bidding under the employee reservation portion ("Employee Discount"). Price Band: Rs. 988 per equity share of face value of Rs. 2 each. The floor price is 494.00 times of the face value of the equity shares. Bids can be made for a minimum of 15 equity shares of face value of Rs. 2 each and in multiples of 15 equity shares of face value of Rs. 2 each thereafter. Discount of Rs. 90.00 per equity share of face value of Rs. 2 is being offered to eligible employees bidding in the employee reservation portion.
Key competitive advantages and factors to consider before investing.
Live demand across investor categories.
Track real-time subscription levels:
*Real-time data subject to exchange updates
Our Company was incorporated as `Symbiotec Pharmalab Private Limited' as a private limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated September 20, 2002, issued by the Registrar of Companies, Madhya Pradesh and Chhattisgarh. Subsequently, in the interest of business expansion and issuing fresh shares to the public to meet requirements of funds for a project being undertaken by the Company which would have resulted into increase in the members of the Company beyond fifty, our Company was converted from a private limited company to a public limited company, pursuant to the Board resolution dated September 22, 2005 and a resolution passed in the extraordinary general meeting of our Shareholders held on October 18, 2005 and the name of our Company was changed to Symbiotec Pharmalab Limited, and a certificate of change of name dated October 27, 2005 was issued to our Company by the Registrar of Companies, Madhya Pradesh & Chhattisgarh. Further, considering the absence of public involvement in the shareholding pattern and the management of the Company, our Company was converted to a private limited company pursuant to the Board resolution dated April 23, 2014 and a resolution passed in the extraordinary general meeting of our Shareholders on May 22, 2014 and the name of our Company was changed to Symbiotec Pharmalab Private Limited and a certificate of incorporation, consequent upon conversion to a private limited was issued by the RoC on July 25, 2014. Thereafter, as part of the Company's strategic vision for future growth and expansion, our Company was converted into a public company, pursuant to the Board resolution dated September 11, 2025 and a special resolution dated September 12, 2025 passed in the extraordinary general meeting of our Shareholders. Consequently the name of our Company was changed to Symbiotec Pharmalab Limited and a fresh certificate of incorporation dated September 26, 2025, consequent upon conversion to a public company, was issued by the Registrar of Companies, Central Processing Centre.
Amount in ₹ crore
Amount in ₹ crore
Figures in ₹ crore, on a consolidated basis, as reported for FY24 to FY26.
*Subject to approvals and market conditions.